According to the latest research publication of IMARC Group, the size of the genetics market in Saudi Arabia has reached USD 229.8 Million in 2025. The market is expected to reach USD 616.5 Million in 2034, showing a growth rate (CAGR) of 11.59% during the period 2026-2034.
How AI is changing the future of the Saudi Arabian Genomics market
- Rapid Genome Sequencing Analysis: The AI-driven bioinformatics pipeline at Genalive’s Riyadh facility processes 1,000 genomes each month, with a planned rate of up to 5,000 each month, reducing translation time from days to hours while identifying pathogenic mutations with a high accuracy of 35%.
- Disease Risk Model: Machine learning methods analyze genetic variants as well as clinical and environmental factors, enabling the identification of people at high risk of chronic conditions such as diabetes and heart disease, which currently account for the majority of Saudi Arabia’s disease burden.
- Development of Personalized Medicine: AI combines medical, genomic, and behavioral data to coordinate medical interventions based on individual genes, bringing the Government closer to the correct goals of medicine under the Vision 2030 Health Sector Reform Program with more than 3,000 jobs created in bioinformatics.
How Vision 2030 is changing Saudi Arabia’s Genomics industry
Vision 2030 has put genomics at the heart of Saudi Arabia’s health care reform strategy, channeling SAR 50 billion (USD 13.33 billion) into health care infrastructure. The large Saudi Human Genome Program, established by Crown Prince Mohammed bin Salman in 2018 and managed by King Abdulaziz City for Science and Technology, aims to sequence 100,000 Saudi genes – up to 63,000 genes representing 63% of the completion of genetics dealing with his Kingdom. affecting 8% of births and 20% of the population due to 56% consanguinity rates. BGI Genomics has received an important three-year NUPCO contract to provide 930,000 genetic testing services at 83 public hospitals, including gene sequencing, genome sequencing, and cancer genetic testing.
Download a Sample Report to Understand Market Trends and Outlook
Market Trends and Drivers:
National Genomics Infrastructure Capacity to Drive
Saudi Arabia’s genomics market is growing rapidly due to the government’s strategic investments in building independent genomic capacity and reducing reliance on international laboratories. The establishment of Genalive in 2023 – an advanced clinical genomics laboratory of 4,000 square meters in Riyadh developed in collaboration between BGI Genomics and Tibbiyah Holding – represents one of the most advanced environmental facilities, high-quality sequencing houses and one of the largest healthcare facilities in the Middle East. Eight genomic laboratories now operate across the country providing accessible diagnostic services, while the Saudi-German Genomic Center provides comprehensive diagnostic services across the GCC using the latest sequencing technologies.
Addressing the High Burden of Genetic Disease through Population-Based Research
Saudi Arabia faces unique public health challenges stemming from high intermarriage rates, creating an urgent need for genomic solutions tailored to the Kingdom’s population. With a 56% rate of consanguinity among the highest in the world, the prevalence of genetic diseases including beta-thalassemia, sickle cell anemia, and various metabolic diseases puts a huge strain on the health system. Genetic conditions affect approximately 8% of births and 20% of the general population, driving high health care costs and reducing the quality of life of affected families. The Saudi Genome Program directly addresses these challenges by mapping genetic diversity in the Saudi population, identifying 3,000 new mutations that cause 1,230 rare diseases and creating 25 genetic panels for targeted screening.
Next Generations Adoption and Cost Reduction to Accelerate Access
Advances in DNA sequencing technologies, particularly next-generation sequencing, are truly changing the dynamics of the genomics market by making comprehensive genetic analysis economically feasible in a population-based manner. The cost of whole genome sequencing has fallen by 60% since the Saudi Genome Program began, dropping from historical levels of more than USD 100,000 to around USD 1,000 per genome, with estimates suggesting further reductions enabling mass screening efforts. This incredible cost pressure makes genetic testing accessible to people, enabling rapid diagnosis and individualized treatment plans in contrast to advanced economic conditions rather than limiting genetics to high-end medical centers or wealthy patients.
Saudi Arabia Genomics Market Industry Segmentation:
The report has segmented the market into the following categories:
Features details:
- Products
- Hardware and Software
- Materials and reagents
- Services
- Core Genomics Services
- NGS-based services
- Biomarker Translation Services
- Computational Services
- Others
Usage Notes:
- Functional genomics
- Epigenomics
- Discovery of Biomarkers
- Road Analysis
- Others
Technical details:
- Sequence
- Microarray
- Polymerase Chain Reaction
- Nucleic Acid Extraction and Purification
- Others
End user reviews:
- Research Institutes
- Hospitals and Clinics
- Pharmaceutical and Biotechnology Companies
- Others
Field Descriptions:
- In the North and Central Region
- Western Region
- Eastern region
- The area is in the South
Competitive landscape:
The competitive landscape of the industry has also been analyzed along with profiles of key players.
Recent News and Developments in the Saudi Arabian Genomics Market
- September 2025: BGI Genomics unveiled “i99”, an AI-driven health management platform that integrates genomic, epigenetic, microbiome, imaging, and lifestyle data to generate actionable data for disease prevention and long-term health planning aligned with Saudi Vision 2030.
- January 2025: Genalive was awarded a three-year contract by the National Unified Procurement Company (NUPCO) under the Saudi Ministry of Health, providing more than 930,000 genetic testing services in 83 public hospitals across the Kingdom.
- November 2024: The Ministry of Investment (MISA) partnered with Novartis to strengthen Saudi Arabia’s biopharmaceutical capacity through local investments in cell and gene therapy, science transfer, and medical research, which contributed approximately $857 million to GDP.
Note: If you need specific information, details, or information not included in this report, we are happy to receive your request. As part of our personalization service, we will collect and provide additional information that you require, based on your specific needs. Please let us know your exact requirements and we will ensure that the report is updated according to your expectations.
#Saudi #Arabia #Genomics #Market #Precision #Medicine #DNA #Sequencing #Growth #Outlook